title: Polypharmacy or medication washout: an old tool revisited.
abstract: There has been a rapid increase in the use of polypharmacy in psychiatry possibly due to the introduction of newer drugs, greater availability of these newer drugs, excessive confidence in clinical trial results, widespread prescribing of psychotropic medications by primary care, and pressure to augment with additional medications for unresolved side effects or greater efficacy. Even the new generation of medications may not hold significant advantages over older drugs. In fact, there may be additional safety risks with polypharmacy being so widespread. Washout, as a clinical tool, is rarely done in medication management today. Studies have shown that augmenting therapy with additional medications resulted in 9.1%-34.1% dropouts due to intolerance of the augmentation, whereas studies of medication washout demonstrated only 5.9%-7.8% intolerance to the washout procedure. These perils justify reconsideration of medication washout before deciding on augmentation. There are unwarranted fears and resistance in the medical community toward medication washout, especially at the moment a physician is trying to decide whether to washout or add more medications to the treatment regimen. However, medication washout provides unique benefits to the physician: it establishes a new baseline of the disorder, helps identify medication efficacy from their adverse effects, and provides clarity of diagnosis and potential reduction of drug treatments, drug interactions, and costs. It may also reduce overall adverse events, not to mention a potential to reduce liability. After washout, physicians may be able to select the appropriate polypharmacy more effectively and safely, if necessary. Washout, while not for every patient, may be an effective tool for physicians who need to decide on whether to add potentially risky polypharmacy for a given patient. The risks of washout may, in some cases, be lower and the benefits may be clearly helpful for diagnosis, understanding medication effects, the doctor/patient relationship, and safer use of polypharmacy if indicated.
authors.affiliation: Neuro-Therapy Clinic Inc, Denver, CO.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Hoffman
authors.forename: Mark
authors.initials: M
authors.lastname: Schiller
authors.forename: James M
authors.initials: JM
authors.lastname: Greenblatt
authors.forename: Dan V
authors.initials: DV
authors.lastname: Iosifescu
references.citation: Schizophr Res. 2011 Mar;126(1-3):11-9
references.pmid: 21183318
references.citation: Control Clin Trials. 2004 Feb;25(1):119-42
references.pmid: 15061154
references.citation: Schizophr Bull. 2003;29(1):15-31
references.pmid: 12908658
references.citation: Psychother Psychosom. 2007;76(5):260-5
references.pmid: 17700045
references.citation: CNS Drugs. 2008;22(7):587-602
references.pmid: 18547127
references.citation: Am J Psychiatry. 2004 Apr;161(4):700-6
references.pmid: 15056517
references.citation: J Clin Psychiatry. 2006 Mar;67(3):453-60
references.pmid: 16649833
references.citation: J Psychiatr Pract. 2007 Mar;13(2):97-105
references.pmid: 17414685
references.citation: Psychiatr Serv. 2001 Aug;52(8):1033-6
references.pmid: 11474046
references.citation: J Clin Invest. 2009 Apr;119(4):700-5
references.pmid: 19339761
references.citation: Bipolar Disord. 2008 Dec;10(8):957-68
references.pmid: 19594510
references.citation: J Clin Psychiatry. 2010 Apr;71(4):463-74
references.pmid: 20156410
references.citation: J Clin Psychiatry. 2009 Feb;70(2):155-62
references.pmid: 19210946
references.citation: Clin Geriatr Med. 1992 Feb;8(1):143-58
references.pmid: 1576572
references.citation: Arch Gen Psychiatry. 2010 Jan;67(1):26-36
references.pmid: 20048220
references.citation: Am J Geriatr Pharmacother. 2007 Dec;5(4):345-51
references.pmid: 18179993
references.citation: Jt Comm J Qual Patient Saf. 2008 Oct;34(10):571-82
references.pmid: 18947117
references.citation: Br J Psychiatry. 1998 Oct;173:325-9
references.pmid: 9926037
references.citation: Am J Psychiatry. 2006 Feb;163(2):175-6
references.pmid: 16449464
references.citation: J Clin Psychiatry. 2008 Jul;69(7):1064-74
references.pmid: 18399725
references.citation: Am Fam Physician. 2000 Mar 1;61(5):1437-46
references.pmid: 10735348
references.citation: Arch Gen Psychiatry. 1997 Jan;54(1):49-55
references.pmid: 9006400
references.citation: Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006117
references.pmid: 19370626
references.citation: N Engl J Med. 2011 May 26;364(21):2037-42
references.pmid: 21612472
references.citation: Psychother Psychosom. 2010;79(5):267-79
references.pmid: 20616621
references.citation: J Psychiatr Res. 2011 Jan;45(1):64-75
references.pmid: 20598710
references.citation: CMAJ. 1999 Jul 27;161(2):143-5
references.pmid: 10439822
references.citation: Am J Psychiatry. 2011 Jul;168(7):689-701
references.pmid: 21536692
references.citation: Cleve Clin J Med. 2008 Jan;75(1):57-66
references.pmid: 18236731
references.citation: JAMA. 2011 Aug 3;306(5):493-502
references.pmid: 21813427
references.citation: Am J Psychiatry. 1997 Dec;154(12):1747-50
references.pmid: 9396956
references.citation: Br J Psychiatry. 2006 Feb;188:122-7
references.pmid: 16449697
references.citation: Psychiatry Res. 2010 Apr 30;176(2-3):109-13
references.pmid: 20185182
references.citation: Can J Psychiatry. 2007 Sep;52(9):553-62
references.pmid: 17953159
references.citation: MedGenMed. 2003 Aug 04;5(3):16
references.pmid: 14600653
references.citation: Am J Psychiatry. 2009 Sep;166(9):980-91
references.pmid: 19687129
references.citation: CNS Drugs. 2010 Jan;24(1):35-53
references.pmid: 20030418
references.citation: J Affect Disord. 2003 Aug;75(3):291-6
references.pmid: 12880942
references.citation: CNS Drugs. 2010 Apr;24(4):319-26
references.pmid: 20297856
references.citation: J Clin Psychiatry. 2000 Jan;61(1):9-15
references.pmid: 10695639
references.citation: Am J Psychiatry. 2006 Nov;163(11):1905-17
references.pmid: 17074942